IR@PKUHSC  > 北京大学临床肿瘤学院  > 胃肠肿瘤中心
学科主题临床医学
Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine
Yu, Jingwei; Gao, Jing; Lu, Zhihao; Li, Yilin; Shen, Lin
关键词Advanced Gastric Cancer Serum Tubb3 Paclitaxel Capecitabine
刊名MEDICAL ONCOLOGY
2012-12-01
DOI10.1007/s12032-012-0292-y
29期:5页:3029-3034
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
关键词[WOS]III BETA-TUBULIN ; PHASE-II ; CHEMOTHERAPY ; EXPRESSION ; CISPLATIN ; TRIAL ; 5-FLUOROURACIL ; METAANALYSIS ; MULTICENTER ; MARKER
英文摘要

The overexpression of beta-tubulin III (TUBB3) in tumor tissues was reversely related with the efficacy of paclitaxel and clinical outcome in different cancers. In this study, we aimed to investigate the association between serum levels of TUBB3 and clinical outcome in advanced gastric cancer patients receiving first-line paclitaxel plus capecitabine. One hundred and twenty-eight advanced gastric cancer patients receiving first-line paclitaxel plus capecitabine in Peking University Cancer Hospital from December 2006 to October 2010 were enrolled in the study. Serum samples from 32 healthy individuals were used as controls. TUBB3 expression level in advanced gastric cancer was significantly higher than that in healthy control group (31.6 +/- A 17.8 ng/mL vs. 16.9 +/- A 3.8 ng/mL, p < 0.001). For all patients, the clinical benefit rate (CBR), median progression-free survival (PFS), and overall survival (OS) were 55.6 %, 179 and 306 days, respectively. The CBR, median PFS, and OS in patients with low (n = 27) and high levels (n = 101) of TUBB3 were 95.8 %/45.1 % (low vs. high, p < 0.001), 190 days/166 days (p = 0.064), and 360 days/297 days (p = 0.023), respectively. Cox multivariate regression analysis demonstrated that the serum levels of TUBB3 were an independent prognostic factor for advanced gastric cancer patients (HR = 1.950; 95 % CI, 1.242-3.062; p = 0.004). This study indicated that low levels of TUBB3 in serum could predict better response and survival for advanced gastric cancer patients receiving paclitaxel plus capecitabine, which could be used to select patients who would benefit from this regimen.

语种英语
WOS记录号WOS:000311513800004
项目编号D101100050010023
资助机构Beijing Municipal Science &amp ; Technology Commission
引用统计
被引频次:12[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/53035
专题北京大学临床肿瘤学院_胃肠肿瘤中心
北京大学临床肿瘤学院_消化肿瘤内科
作者单位Peking Univ Canc Hosp & Inst, Dept Gastrointestinal Oncol, Minist Educ, Key Lab Carcinogenesis & Translat Res, Beijing 100142, Peoples R China
推荐引用方式
GB/T 7714
Yu, Jingwei,Gao, Jing,Lu, Zhihao,et al. Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine[J]. MEDICAL ONCOLOGY,2012,29(5):3029-3034.
APA Yu, Jingwei,Gao, Jing,Lu, Zhihao,Li, Yilin,&Shen, Lin.(2012).Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine.MEDICAL ONCOLOGY,29(5),3029-3034.
MLA Yu, Jingwei,et al."Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine".MEDICAL ONCOLOGY 29.5(2012):3029-3034.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Yu, Jingwei]的文章
[Gao, Jing]的文章
[Lu, Zhihao]的文章
百度学术
百度学术中相似的文章
[Yu, Jingwei]的文章
[Gao, Jing]的文章
[Lu, Zhihao]的文章
必应学术
必应学术中相似的文章
[Yu, Jingwei]的文章
[Gao, Jing]的文章
[Lu, Zhihao]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。